US20230285376A1 - Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients - Google Patents

Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients Download PDF

Info

Publication number
US20230285376A1
US20230285376A1 US18/018,031 US202118018031A US2023285376A1 US 20230285376 A1 US20230285376 A1 US 20230285376A1 US 202118018031 A US202118018031 A US 202118018031A US 2023285376 A1 US2023285376 A1 US 2023285376A1
Authority
US
United States
Prior art keywords
lomitapide
patient
daily dose
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US18/018,031
Other languages
English (en)
Inventor
Ruth NALLEN
Tracy CUNNINGHAM
Mark SUMERAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amryt Pharmaceuticals Inc
Original Assignee
Amryt Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amryt Pharmaceuticals Inc filed Critical Amryt Pharmaceuticals Inc
Priority to US18/018,031 priority Critical patent/US20230285376A1/en
Publication of US20230285376A1 publication Critical patent/US20230285376A1/en
Assigned to AMRYT PHARMACEUTICALS INC. reassignment AMRYT PHARMACEUTICALS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOMPHARMACEUTICALS GMBH
Assigned to AMRYT PHARMACEUTICALS INC. reassignment AMRYT PHARMACEUTICALS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMRYT PHARMACEUTICALS DAC
Assigned to SOMPHARMACEUTICALS GMBH reassignment SOMPHARMACEUTICALS GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SUMERAY, Mark
Assigned to AMRYT PHARMACEUTICALS DAC reassignment AMRYT PHARMACEUTICALS DAC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CUNNINGHAM, TRACEY, NALLEN, Ruth
Priority to US19/341,244 priority patent/US20260021087A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • HoFH Homozygous familial hypercholesterolaemia
  • FH Familial Hypercholesterolaemia
  • EAS European Atherosclerosis Society
  • LDL-C levels lead to premature, severe, and progressive atherosclerosis and development of early cardiovascular disease (CVD).
  • LLT lipid-lowering therapy
  • primary prevention is suggested to start as early as possible and mainly consists of lowering LDL-C levels to ⁇ 135 mg/dL ( ⁇ 3.5 mmol/L) in pediatric HoFH patients and to ⁇ 100 mg/dL ( ⁇ 2.5 mmol/L) in adults.
  • Secondary prevention comprises a decrease of LDL-C levels to ⁇ 70 mg/dL ( ⁇ 1.8 mmol/L) in adults with CVD as recommended by the EAS.
  • FIG. 1 shows the mean lomitapide pediatric starting dose (mg) based on PBPK modeling and allometric scaling.
  • FIG. 2 shows the design of the clinical study in Example 2.
  • the present disclosure provides, a method of safely administering lomitapide, or a pharmaceutically acceptable salt thereof, to a pediatric patient comprising:
  • the present disclosure provides a method of treating hyperlipidemia or hypercholesterolemia in a pediatric patient, comprising:
  • a method of treating hyperlipidemia or hypercholesterolemia comprising:
  • a method of treating hyperlipidemia or hypercholesterolemia comprising:
  • the present disclosure provides a method of treating hyperlipidemia or hypercholesterolemia, comprising:
  • the term “about” when immediately preceding a numerical value means a range (e.g., plus or minus 10% of that value).
  • “about 50” can mean 45 to 55
  • “about 25,000” can mean 22,500 to 27,500, etc., unless the context of the disclosure indicates otherwise, or is inconsistent with such an interpretation.
  • “about 50” means a range extending to less than half the interval(s) between the preceding and subsequent values, e.g., more than 49.5 to less than 50.5.
  • the phrases “less than about” a value or “greater than about” a value should be understood in view of the definition of the term “about” provided herein.
  • the term “about” when preceding a series of numerical values or a range of values refers, respectively to all values in the series, or the endpoints of the range.
  • administer refers to either directly administering a compound or pharmaceutically acceptable salt or ester of the compound or a composition comprising the compound or pharmaceutically acceptable salt or ester of the compound to a patient.
  • an effective amount of lomitapide is that amount which is required to reduce at least one symptom of HoFH in a patient, e.g. the amount required to reduce the patient's low-density lipoprotein cholesterol (LDL-C).
  • LDL-C low-density lipoprotein cholesterol
  • the actual amount which comprises the “effective amount” or “therapeutically effective amount” will vary depending on a number of conditions including, but not limited to, the severity of the disorder, the size and health of the patient, and the route of administration. A skilled medical practitioner can readily determine the appropriate amount using methods known in the medical arts.
  • the phrase “pediatric patient” as used herein refers to a patient less than 18 years of age.
  • phrases “pharmaceutically acceptable” as used herein refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • salts as used herein embraces pharmaceutically acceptable salts commonly used to form alkali metal salts of free acids and to form addition salts of free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable.
  • salts also includes solvates of addition salts, such as hydrates, as well as polymorphs of addition salts.
  • Suitable pharmaceutically acceptable acid addition salts can be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid.
  • Appropriate organic acids can be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, and heterocyclyl containing carboxylic acids and sulfonic acids, for example formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, 3-hydroxybutyric, galactaric and galactu
  • treating refers to improving at least one symptom of the patient's disorder. Treating can be improving, or at least partially ameliorating a disorder.
  • the term “therapeutic effect” as used herein refers to a desired or beneficial effect provided by the method and/or the composition.
  • the method for treating HoFH provides a therapeutic effect when the method reduces at least one symptom of HoFH, e.g., reduce low-density lipoprotein cholesterol (LDL-C), in a patient.
  • LDL-C low-density lipoprotein cholesterol
  • Lomitapide is a first in class oral, selective inhibitor of microsomal transfer protein (MTP), an intracellular lipid-transfer protein that is found in the lumen of the endoplasmic reticulum and is responsible for binding and shuttling individual lipid molecules between membranes.
  • MTP microsomal transfer protein
  • MTP plays a key role in the assembly of apo B containing lipoproteins in the liver and intestines. Inhibition of MTP reduces lipoprotein secretion and circulating concentrations of lipoprotein-borne lipids including cholesterol and triglycerides.
  • lomitapide N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4′(trifluoromethyl) [1,1′-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9H-fluorene-9-carboxamide. Its structural formula is:
  • Lomitapide and other inhibitors of MTP-mediated neutral lipid transfer activity are described, for example, in U.S. Pat. Nos. 5,789,197, 5,883,109, 6,066,653, and 6,492,365, each of which is incorporated herein by reference in its entirety. MTP inhibitors are described throughout U.S. Pat. No. 6,066,653, in particular in columns 3-28.
  • Lomitapide and methods for its use are described, for example, in U.S. Pat. Nos. 7,932,268; 8,618,135; 9,265,758; 9,364,470; 9,433,617; 9,861,622, 10,016,404, and 10,555,938 each of which is incorporated by reference herein in its entirety. See also U.S. Pat. No. 10,213,419 the entirety of which is incorporated herein by reference.
  • Lomitapide is a “lipid modifying agent” according to the Anatomical Therapeutic Chemical (ATC) Classification System (ATC code C10AX12). It is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LA in adult patients with HoFH. Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g., nephrotic syndrome, hypothyroidism) must be excluded.
  • Lojuxta is not approved in pediatric patients (i.e., in patients less than 18 years of age) because the safety and efficacy of lomitapide in this sensitive population has not been established.
  • compositions lomitapide or a pharmaceutically acceptable salt thereof, in the amounts described herein, may be compounded according to accepted pharmaceutical practice with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in the particular type of unit dosage form.
  • dosage forms can be administered to the patient on a regimen of one to four doses per day.
  • the disclosure provides tablets containing a lomitapide composition as described herein.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin, microcrystalline cellulose, or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent.
  • Tablets, and other solid dosage forms may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art.
  • the disclosed excipients may serve more than one function.
  • fillers or binders may also be disintegrants, glidants, anti-adherents, lubricants, sweeteners and the like.
  • Liquid formulations can also be prepared by dissolving or suspending one or the combination of active substances in a conventional liquid vehicle acceptable for pharmaceutical administration so as to provide the desired dosage in one to four teaspoonsfuls.
  • Dosage units including tablets, capsules and caplets, of various sizes can be prepared, e.g., of about 2 to 10000 mg in total weight, containing one or both of the active substances in the ranges described above, with the remainder being a physiologically acceptable carrier of other materials according to accepted pharmaceutical practice.
  • These tablets can, of course, be scored to provide for fractional doses.
  • Gelatin capsules can be similarly formulated.
  • a scored tablet may provide the dosage unit.
  • the subject Under the direction of a physician or other medical professional, the subject may be directed to take one portion of the dosage unit, wherein the one portion will provide the desired dosage level for given interval. At the following interval, the patient may be instructed to take two or more portions of the dosage unit wherein the two or more portions will provide the desired dosage level for that interval.
  • Formulations of lomitapide are commercially available, for example, as Juxtapid capsules.
  • Each Juxtapid capsule contains lomitapide mesylate equivalent to 5, 10, 20, or 30 mg lomitapide free base and the following inactive ingredients: pregelatinized starch, sodium starch glycolate, microcrystalline cellulose, lactose monohydrate, silicon dioxide and magnesium stearate.
  • the capsule shells of all strengths contain gelatin and titanium dioxide; the 5 mg, 10 mg and 30 mg capsules also contain red iron oxide; and the 30 mg capsules also contain yellow iron oxide.
  • the imprinting ink contains shellac, black iron oxide, and propylene glycol.
  • the scope of the present disclosure is not limited to dosage strengths of Juxtapid presently available commercially, and includes capsules containing lomitapide mesylate (or other pharmaceutically acceptable salts of lomitapide) equivalent to 5, 10, 20, 30, 40, or 60 mg lomitapide free base.
  • the present disclosure provides methods of safely administering lomitapide to pediatric HoFH patients. It will be understood that in embodiments of the methods provided herein, the patient is a human.
  • the disclosure provides methods for treating hyperlipidemia or hypercholesterolemia (e.g., Homozygous Familial Hypercholesterolaemia (HoFH)) by administering an effective and tolerable amount of lomitapide or a pharmaceutically acceptable salt thereof, to a pediatric patient in need thereof.
  • An effective amount is an amount sufficient significantly reduce hyperlipidemia or hypercholesterolemia (e.g., HoFH) symptoms or to alleviate those symptoms.
  • Formulations employed in the present methods can incorporate lomitapide or a pharmaceutically acceptable salt thereof into a formulation such that the formulation provides therapeutically effective blood plasma levels of lomitapide or a pharmaceutically acceptable salt thereof for the treatment of hyperlipidemia or hypercholesterolemia (e.g., HoFH).
  • a therapeutically effective dose is achieved by starting the patient on an initial daily dose and titrating to an efficacious and tolerated dose by gradually modifying (e.g., increasing or decreasing) the daily administered amount of lomitapide or a pharmaceutically acceptable salt thereof until a dose that is effective and tolerated is achieved (e.g., the patient with hyperlipidemia or hypercholesterolemia (Homozygous Familial Hypercholesterolaemia (HoFH)) is treated).
  • the efficacious dose is a dose that improves at least one symptom of the patient's Homozygous Familial Hypercholesterolaemia (HoFH), or hyperlipidemia or hypercholesterolemia.
  • the efficacious dose is a dose that reduces the patient's LDL-C to ⁇ 135 mg/dL (3.5 mmol/L).
  • the lomitapide or a pharmaceutically acceptable salt thereof is administered in escalating doses.
  • the escalating doses comprise at least a first dose level and a second dose level.
  • the escalating doses comprise at least a first dose level, a second dose level, and a third dose level.
  • the escalating doses further comprise a fourth dose level.
  • the escalating doses further comprise a fifth dose level.
  • the escalating doses comprise a first dose level, a second dose level, a third dose level, a fourth dose level and a fifth dose level. In some embodiments, six, seven, eight, nine and ten dose levels are contemplated.
  • each dose level is no more than 60% of the immediately following dose level. In embodiments, each dose level is no more than 50% of the immediately following dose level. In embodiments, each dose level is no more than 40% of the immediately following dose level. In some embodiments, each dose level is no more than 33% of the immediately following dose level. In some embodiments, each dose level is no more than 20% of the immediately following dose level. In some embodiments, dose levels are separated by 12 log units. In some embodiments, dose levels are separated by 1 log unit.
  • the present disclosure provides a method of safely administering lomitapide, or a pharmaceutically acceptable salt thereof, to a pediatric patient comprising:
  • the method of safely administering lomitapide, or a pharmaceutically acceptable salt thereof, to a pediatric patient comprises administering a first daily dose of about 2 mg of lomitapide, or a pharmaceutically acceptable salt thereof to a patient aged 5 to 15 years.
  • the method of safely administering lomitapide, or a pharmaceutically acceptable salt thereof, to a pediatric patient comprises administering a first daily dose of about 5 mg of lomitapide, or a pharmaceutically acceptable salt thereof to a patient aged 16 to 17 years.
  • the present disclosure provides a method of treating hyperlipidemia or hypercholesterolemia in a pediatric patient, comprising:
  • the method of treating hyperlipidemia or hypercholesterolemia in a pediatric patient comprises administering a first daily dose of about 2 mg of lomitapide, or a pharmaceutically acceptable salt thereof to a patient aged 5 to 15 years.
  • the method of treating hyperlipidemia or hypercholesterolemia in a pediatric patient comprises administering a first daily dose of about 5 mg of lomitapide, or a pharmaceutically acceptable salt thereof to a patient aged 16 to 17 years.
  • the present disclosure provides a method of treating hyperlipidemia or hypercholesterolemia, comprising:
  • the present disclosure provides a method of treating hyperlipidemia or hypercholesterolemia, comprising:
  • the present disclosure provides a method of treating hyperlipidemia or hypercholesterolemia, comprising:
  • the first daily dose is administered to the patient for about 4 weeks. In embodiments, the first daily dose is administered for about 1 week to about 6 weeks, including about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, or about 6 weeks, including all values and subranges therebetween.
  • each dose level of lomitapide or a pharmaceutically acceptable salt thereof is administered to the subject for from 2 days to 30 weeks, or more. In some embodiments each dose level is administered to the subject for from about 1 week to about 12 weeks. In some embodiments, each dose level is administered to the subject for about 1 week to about 5 weeks. In some embodiments each dose level is administered to the subject from about 1 to about 4 weeks. In some embodiments each dose level is administered to the subject from about 1 to about 3 weeks. In some embodiments each dose level is administered to the subject from about 1 to about 2 weeks.
  • lomitapide or a pharmaceutically acceptable salt is administered. In some embodiments, lomitapide mesylate is administered. In some embodiments, lomitapide or a pharmaceutically acceptable salt thereof is administered orally.
  • lomitapide or a pharmaceutically acceptable salt thereof is administered in a daily dose of about 0.1 mg to about 100 mg to a pediatric patients with hyperlipidemia or hypercholesterolemia (Homozygous Familial Hypercholesterolaemia (HoFH)) in need thereof, including about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 1 mg, about 2 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg to about 100 mg, including any subrange or value therebetween.
  • hyperlipidemia or hypercholesterolemia Homozygous Familial Hypercholesterolaemia (HoFH)
  • HoFH Hypercholesterolemia
  • about 2 mg to about 60 mg of lomitapide or a pharmaceutically acceptable salt thereof is administered on a daily basis. In some embodiments, about 2 mg to about 20 mg of lomitapide or a pharmaceutically acceptable salt thereof is administered on a daily basis. In some embodiments, about 2 mg to about 40 mg of lomitapide or a pharmaceutically acceptable salt thereof is administered on a daily basis.
  • the pediatric patient in need of hyperlipidemia or hypercholesterolemia (e.g., Homozygous Familial Hypercholesterolaemia (HoFH)) treatment is administered a daily dose of 2 mg of lomitapide or a pharmaceutically acceptable salt thereof in the first dosing period, a daily dose of 2 mg of lomitapide or a pharmaceutically acceptable salt thereof in the second dosing period, and a daily dose of 5 mg of lomitapide or a pharmaceutically acceptable salt thereof in the third dosing period, a daily dose of 10 mg of lomitapide or a pharmaceutically acceptable salt thereof in the fourth dosing period, and a daily dose of 20 mg of lomitapide or a pharmaceutically acceptable salt thereof in the fifth dosing period.
  • HoFH Homozygous Familial Hypercholesterolaemia
  • the pediatric patient in need of hyperlipidemia or hypercholesterolemia (e.g., Homozygous Familial Hypercholesterolaemia (HoFH)) treatment is administered a daily dose of 2 mg of lomitapide or a pharmaceutically acceptable salt thereof in the first dosing period, a daily dose of 5 mg of lomitapide or a pharmaceutically acceptable salt thereof in the second dosing period, and a daily dose of 10 mg of lomitapide or a pharmaceutically acceptable salt thereof in the third dosing period, a daily dose of 20 mg of lomitapide or a pharmaceutically acceptable salt thereof in the fourth dosing period, and a daily dose of 40 mg of lomitapide or a pharmaceutically acceptable salt thereof in the fifth dosing period.
  • HoFH Homozygous Familial Hypercholesterolaemia
  • the pediatric patient in need of hyperlipidemia or hypercholesterolemia (e.g., Homozygous Familial Hypercholesterolaemia (HoFH)) treatment is administered a daily dose of 5 mg of lomitapide or a pharmaceutically acceptable salt thereof in the first dosing period, a daily dose of 10 mg of lomitapide or a pharmaceutically acceptable salt thereof in the second dosing period, and a daily dose of 20 mg of lomitapide or a pharmaceutically acceptable salt thereof in the third dosing period, a daily dose of 40 mg of lomitapide or a pharmaceutically acceptable salt thereof in the fourth dosing period, and a daily dose of 60 mg of lomitapide or a pharmaceutically acceptable salt thereof in the fifth dosing period.
  • HoFH Homozygous Familial Hypercholesterolaemia
  • the first dosing period, second dosing period, or third dosing period is about or at least about 1-8 weeks, including about or at least about 1 week, about or at least about 2 weeks, about or at least about 3 weeks, about or at least about 4 weeks, about or at least about 5 weeks, about or at least about 6 weeks, about or at least about 7 weeks, or about or at least about 8 weeks, including all subranges and values therebetween.
  • the patient's age is from 5 to 10 years, from 11 to 15 years, or from 16 to 17 years.
  • the lomitapide is provided to the patient as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis.
  • concomitant lipid-lowering treatments include one or more of the following: statins, ezetimibe, nicotinic acid, bile acid sequestrant, fibrate, and apheresis.
  • the low-fat diet comprises a diet wherein less than about 30% of patient's total calories are from fat, less than about 20% of patient's total calories are from fat, less than about 15% of patient's total calories are from fat, or less than about 10% of patient's total calories are from fat. In some embodiments, the low-fat diet comprises a diet wherein less than about 20% of patient's total calories are from fat.
  • patients receiving lipid lowering therapies during treatment with lomitapide are administered dietary supplements that provided approximately 400 international units vitamin E, 210 mg alpha-linolenic acid (ALA), 200 mg linoleic acid, 110 mg eicosapentaenoic acid (EPA), and 80 mg docosahexaenoic acid (DHA) per day.
  • dietary supplements that provided approximately 400 international units vitamin E, 210 mg alpha-linolenic acid (ALA), 200 mg linoleic acid, 110 mg eicosapentaenoic acid (EPA), and 80 mg docosahexaenoic acid (DHA) per day.
  • administration of lomitapide to a pediatric patient reduces one or more of the following: low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
  • LDL-C low-density lipoprotein cholesterol
  • TC total cholesterol
  • apo B apolipoprotein B
  • non-HDL-C non-high density lipoprotein cholesterol
  • the lomitapide is provided to the patient as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis.
  • administration of lomitapide to a pediatric patient reduces one or more of the following: low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
  • LDL-C low-density lipoprotein cholesterol
  • TC total cholesterol
  • apo B apolipoprotein B
  • non-HDL-C non-high density lipoprotein cholesterol
  • administration of lomitapide to a pediatric patient as an adjunct to a low-fat diet and other lipid-lowering treatments reduces one or more of the following: low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high density lipoprotein cholesterol (non-HDL-C) by about or at least about 10% to about or at least about 90% or more, including about or at least about 10%, about or at least about 20%, about or at least about 30%, about or at least about 40%, about or at least about 50%, about or at least about 60%, about or at least about 70%, about or at least about 80%, about or at least about 90%, or more, including all values and subranges therebetween.
  • LDL-C low-density lipoprotein cholesterol
  • TC total cholesterol
  • apo B apolipoprotein B
  • non-HDL-C non-high density lipoprotein cholesterol
  • the maximum dose in a pediatric patient with Child-Pugh A aged from 5 to 10 years is 10 mg.
  • the maximum dose in a pediatric patient with Child-Pugh A aged from 11 to 15 years is 20 mg.
  • the maximum dose in a pediatric patient with Child-Pugh A aged from 11 to 15 years is 40 mg.
  • the patient's age is from 5 to 10 years and the daily dose of lomitapide in the first dosing period is 2 mg, the daily dose of lomitapide in the second dosing period is 2 mg, and the daily dose of lomitapide in the third dosing period is 5 mg, the daily dose of lomitapide in the fourth dosing period is 10 mg.
  • the first dosing period is about or at least about 4 weeks
  • the second dosing period is about or at least about 4 weeks
  • the third dosing period is about or at least about 4 weeks
  • the fourth dosing period is about or at least about 4 weeks
  • the fifth dosing period is about or at least about 4 weeks.
  • the first, second, third, fourth, and fifth dosing periods are each about 4 weeks ⁇ 3 days.
  • the patient's age is from 11 to 15 years and the daily dose of lomitapide in the first dosing period is 2 mg, the daily dose of lomitapide in the second dosing period is 5 mg, the daily dose of lomitapide in the third dosing period is 10 mg, the daily dose of lomitapide is about 20 mg in the fourth dosing period, the daily dose is about 40 mg in the fifth dosing period.
  • the first dosing period is about or at least about 4 weeks
  • the second dosing period is about or at least about 4 weeks
  • the third dosing period is about or at least about 4 weeks
  • the fourth dosing period is about or at least about 4 weeks
  • the fifth dosing period is about and at least about 4 weeks.
  • the first, second, third, fourth, and fifth dosing periods are each about 4 weeks ⁇ 3 days.
  • the patient's age is 16 to 17 years and the daily dose of lomitapide in the first dosing period is about 5 mg, the daily dose of lomitapide in the second dosing period is about 10 mg, the daily dose of lomitapide in the third dosing period is about 20 mg, the daily dose of lomitapide in the fourth dosing period is about 40 mg, and the daily dose of lomitapide in the fifth dosing period is about 60 mg.
  • the first dosing period is about or at least about 4 weeks
  • the second dosing period is about or at least about 4 weeks
  • the third dosing period is about or at least about 4 weeks
  • the fourth dosing period is about or at least about 4 weeks
  • the fifth dosing period is about or at least about 4 weeks.
  • the first, second, third, fourth, and fifth dosing periods are each about 4 weeks ⁇ 3 days.
  • the daily dose is administered as a single dose or divided into 2 or 3 equal or unequal doses.
  • the lomitapide is administered once-daily at bedtime.
  • lomitapide mesylate in an amount equivalent to about 2-60 mg of the lomitapide free base is administered. In some embodiments, lomitapide mesylate in an amount equivalent to about 2 mg of the lomitapide free base is administered. In some embodiments, lomitapide mesylate in an amount equivalent to about 2.5 mg of the lomitapide free base is administered. In some embodiments, lomitapide mesylate in an amount equivalent to about 5 mg of the lomitapide free base is administered. In some embodiments, lomitapide mesylate in an amount equivalent to about 10 mg of the lomitapide free base is administered.
  • lomitapide mesylate in an amount equivalent to about 30 mg of the lomitapide free base is administered. In some embodiments, lomitapide mesylate in an amount equivalent to about 40 mg of the lomitapide free base is administered. In some embodiments, lomitapide mesylate in an amount equivalent to about 60 mg of the lomitapide free base is administered.
  • the patient has homozygous familial hypercholesterolemia.
  • kits for use in treating hyperlipidemia or hypercholesterolemia e.g., Homozygous Familial Hypercholesterolaemia (HoFH)
  • hyperlipidemia or hypercholesterolemia e.g., Homozygous Familial Hypercholesterolaemia (HoFH)
  • kits comprise lomitapide or a pharmaceutically salt thereof.
  • the kits of the present disclosure may be used for administering lomitapide or a pharmaceutically acceptable salt thereof at different dosage intervals, or for titrating the dose of lomitapide or a pharmaceutically acceptable salt thereof according to methods described herein.
  • kits for treating hyperlipidemia or hypercholesterolemia e.g., Homozygous Familial Hypercholesterolaemia (HoFH)
  • hyperlipidemia or hypercholesterolemia e.g., Homozygous Familial Hypercholesterolaemia (HoFH)
  • HoFH Homozygous Familial Hypercholesterolaemia
  • kits of the present disclosure may comprise directions for administration.
  • the kit can include instructions to administer lomitapide or a pharmaceutically acceptable salt thereof in a suitable manner to perform the methods described herein, e.g., in a suitable dose, dosage form, dosing intervals (e.g., as described herein).
  • the informational material can include instructions to administer the lomitapide or a pharmaceutically acceptable salt thereof to a pediatric patient with hyperlipidemia or hypercholesterolemia (e.g., Homozygous Familial Hypercholesterolaemia (HoFH)).
  • HoFH Homozygous Familial Hypercholesterolaemia
  • the kit can include one or more containers for lomitapide or a pharmaceutically salt thereof as described herein.
  • the kit contains separate containers, dividers or compartments for the composition and informational material.
  • the composition can be contained in a bottle, vial, or syringe.
  • the separate elements of the kit are contained within a single, undivided container.
  • the composition is contained in a bottle, vial or syringe that has attached thereto the informational material in the form of a label.
  • the kit includes a plurality (e.g., a pack) of individual containers, each containing one or more unit dosage forms (e.g., a dosage form described herein) of a composition described herein.
  • the kit can include a plurality of syringes, ampules, or foil packets each containing a single unit dose of a composition described herein.
  • An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • the containers of the kits can be air tight, waterproof (e.g., impermeable to changes in moisture or evaporation), and/or light-tight.
  • kits for safely administering lomitapide, or a pharmaceutically acceptable salt thereof, to a pediatric patient aged 5 to 15 comprising: a first daily dose of about 0.5 mg to about 2.5 mg of lomitapide, or a pharmaceutically acceptable salt thereof.
  • kits for safely administering lomitapide, or a pharmaceutically acceptable salt thereof, to a pediatric patient aged 16 to 17 years comprising a first daily dose of about 2.5 mg to about 7.5 mg of lomitapide, or a pharmaceutically acceptable salt thereof.
  • kits for treating hyperlipidemia or hypercholesterolemia comprising: a first daily dose of about 0.5 mg to about 2.5 mg of lomitapide, or a pharmaceutically acceptable salt thereof.
  • kits for treating hyperlipidemia or hypercholesterolemia comprising a first daily dose of about 2.5 mg to about 7.5 mg of lomitapide, or a pharmaceutically acceptable salt thereof.
  • kits for treating hyperlipidemia or hypercholesterolemia comprising: a first daily dose of about 0.5 mg to about 2.5 mg of lomitapide, or a pharmaceutically acceptable salt thereof.
  • kits for treating hyperlipidemia or hypercholesterolemia comprising: a first daily dose of about 0.5 mg to about 2.5 mg of lomitapide, or a pharmaceutically acceptable salt thereof.
  • kits for treating hyperlipidemia or hypercholesterolemia in a pediatric patient aged 16 to 17 years comprising a first daily dose of about 2.5 mg to about 7.5 mg of lomitapide, or a pharmaceutically acceptable salt thereof.
  • the kit contains a first daily dose to be administered to the pediatric patient for about 1 to 4 weeks, including about 1 week, about 2 weeks, about 3 weeks and about 4 weeks. In some embodiments, the kit contains a first daily dose to be administered to the pediatric patient for about 4 weeks.
  • kits provided herein for treating hyperlipidemia or hypercholesterolemia e.g., Homozygous Familial Hypercholesterolaemia (HoFH)
  • the kit contains a daily dose of 2 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a first dosing period, a daily dose of 2 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a second dosing period, a daily dose of 5 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a third dosing period, a daily dose of 10 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a fourth dosing period, and a daily dose of 20 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a fifth dosing period.
  • HoFH Homozygous Familial Hypercholesterolaemia
  • kits provided herein for treating hyperlipidemia or hypercholesterolemia e.g., Homozygous Familial Hypercholesterolaemia (HoFH)
  • the kit contains a daily dose of 2 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a first dosing period, a daily dose of 5 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a second dosing period, a daily dose of 10 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a third dosing period, a daily dose of 20 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a fourth dosing period, and a daily dose of 40 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a fifth dosing period.
  • HoFH Homozygous Familial Hypercholesterolaemia
  • kits provided herein for treating hyperlipidemia or hypercholesterolemia e.g., Homozygous Familial Hypercholesterolaemia (HoFH)
  • the kit contains a daily dose of 5 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a first dosing period, a daily dose of 10 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a second dosing period, a daily dose of 20 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a third dosing period, a daily dose of 40 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a fourth dosing period, and a daily dose of 60 mg of lomitapide or a pharmaceutically acceptable salt thereof to be administered in a fifth dosing period.
  • HoFH Homozygous Familial Hypercholesterolaemia
  • the kit may comprise lomitapide dosage units for administration to a pediatric patient aged about 5-10 years, or about 11-15 years, or about 16 to ⁇ 17 years.
  • the present disclosure provides a kit for use in any one of the methods disclosed herein, comprising lomitapide dosage units to be administered to a pediatric patient aged about 5-10 years, wherein the dosage units are shown in the Table below. In some embodiments, when the pediatric patient aged about 5-10 years is classified as Child-Pugh A, then the maximum dose is 10 mg.
  • the present disclosure provides a kit for use in any one of the methods disclosed herein, comprising lomitapide dosage units to be administered to a pediatric patient aged about 5-10 years, wherein the dosage units are shown in the Table below.
  • the present disclosure provides a kit for use in any one of the methods disclosed herein, comprising lomitapide dosage units to be administered to a pediatric patient aged about 11-15 years, wherein the dosage units are shown in the Table below. In some embodiments, when the pediatric patient aged about 11-15 years is classified as Child-Pugh A, then the maximum dose is 20 mg.
  • the present disclosure provides a kit for use in any one of the methods disclosed herein, comprising lomitapide dosage units to be administered to a pediatric patient aged about 11-15 years, wherein the dosage units are shown in the Table below.
  • the present disclosure provides a kit for use in any one of the methods disclosed herein, comprising lomitapide dosage units to be administered to a pediatric patient aged about 16 to ⁇ 17 years, wherein the dosage units are shown in the Table below.
  • the maximum dose is 40 mg.
  • the present disclosure provides a kit for use in any one of the methods disclosed herein, comprising lomitapide dosage units to be administered to a pediatric patient aged about 16 to ⁇ 17 years, wherein the dosage units are shown in the Table below.
  • the objective of this study was to use determine pediatric starting doses for different age ranges that yield systemic exposures that are similar to those achieved in adults aged 18-55 following a 5 mg oral dose using allometric scaling and physiologically-based (PBPK) modeling and simulation approaches.
  • PBPK physiologically-based
  • the first allometric scaling approach for oral clearance in pediatrics is based on the PK relationship:
  • AUCsteady state Daily Dose/( CL/F ).
  • Daily Dose pediatrics Daily Dose adults *[(CL/F) pediatrics/(CL/F) adults ]. From this equation, it can be seen that the required daily dose in pediatrics is a function of adult dose, adult oral clearance and pediatric oral clearance.
  • Simcyp population-based simulator (version 12.2) was used to select the doses for pediatrics age groups that will achieve 80-125% AUC geometric mean and Cmax geometric mean in pediatric subjects (2-18 year old, 50% male) compared to mean AUC and Cmax in adults after 5 mg oral dosing (18-55 year old, 50% male). 10 trials were simulated with 20 virtual healthy subjects (adults or children) in each trial. The point estimate and 95% confidence interval around the AUC geometric mean and Cmax geometric mean were compared between different doses.
  • This clinical study is a single-arm, open-label, international, multi-center study to evaluate the efficacy and safety of lomitapide in pediatric patients with Homozygous Familial Hypercholesterolaemia (HoFH) on stable lipid-lowering therapy.
  • HoFH Homozygous Familial Hypercholesterolaemia
  • LDL-C low-density lipoprotein cholesterol
  • MTD maximum tolerated dose
  • lipid parameters including total cholesterol (TC), non high-density lipoprotein cholesterol (Non-HDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglycerides (TG), lipoprotein(a) [Lp(a)], and apolipoprotein B (apo B);
  • EAS European Atherosclerosis Society
  • the primary efficacy endpoint is:
  • the investigational product is supplied in high-density polyethylene bottles with polyester, aluminium foil, and cardboard induction seals and child-resistant polypropylene screw caps. It is packed and labelled according to applicable regulatory requirements.
  • Lomitapide is prepared as a crystalline methanesulfonate salt.
  • the investigational product is administered orally in opaque, hard gelatin capsules.
  • Four bottle types contain 28 capsules each by 2 mg, 5 mg, 10 mg, and 20 mg strength.
  • Each hard capsule contains lomitapide mesylate equivalent to the labeled content of the free-base form of lomitapide, and the following inactive excipients: pregelatinised starch (maize), sodium starch glycolate (Type A), microcrystalline cellulose, lactose monohydrate, colloidal, anhydrous silica, and magnesium stearate.
  • a sufficient number of lomitapide bottles are provided to sites in bulk at appropriate intervals depending on the phase of the study and accrual of patients. Dietary supplements are sourced locally, where possible.
  • the investigator, or the person designated by the investigator are responsible for dispensing the appropriate bottle or combination of bottles to a patient at each study visit.
  • the investigator, or the person designated by the investigator is responsible for keeping accurate records of study medication accountability comprising the receipt, the dispensing, and the return of all used and partially unused study medication throughout the study.
  • the drug accountability form is kept up to date and will be reviewed periodically by the study monitor. Patients are asked to keep all used and partially unused bottles of study medication and return them to the site during the scheduled visits.
  • Patients are administered daily oral supplementation with vitamin E (200 IU for patients 5 to 8 years of age, 400 IU for patients 9 to ⁇ 17 years of age) and an EFA supplement containing approximately 200 mg linoleic acid, 210 mg ALA, 110 mg EPA, and 80 mg DHA. Dietary supplements is dispensed during Visit 3 at Week ⁇ 3 to Week ⁇ 2 (Run-in Compliance), during Visit 4 at DO (Baseline, Efficacy Phase), and at every visit thereafter until Visit 21 at Week 92 ⁇ 1 week.
  • vitamin E 200 IU for patients 5 to 8 years of age, 400 IU for patients 9 to ⁇ 17 years of age
  • EFA supplement containing approximately 200 mg linoleic acid, 210 mg ALA, 110 mg EPA, and 80 mg DHA.
  • Dietary supplements is dispensed during Visit 3 at Week ⁇ 3 to Week ⁇ 2 (Run-in Compliance), during Visit 4 at DO (Baseline, Efficacy Phase), and at every visit thereafter until Visit 21 at Week
  • GI AEs associated with the use of lomitapide decreases in the presence of a low-fat diet. Patients start to follow a diet supplying ⁇ 20% of energy from fat or ⁇ 30 g fat, whichever is the lesser amount at Visit 2, the Start of the Run-in Period, and continue this diet until the EoT (and the LTE of this study, when applicable).
  • a dietitian provides dietary counseling to the patients and their parents/legal guardians from Visit 2 (Start of the Run-in Period) through Visit 5 at Week 4 ⁇ 3 days. Patients and parents/legal guardians are instructed on how to consume ⁇ 20% energy from fat or ⁇ 30 g fat, whichever is the lesser amount. Instructions include detailed information concerning the role of dietary fat and GI-related symptoms and patients are encouraged to pay special attention to foods they eat when/if they experience these symptoms. The dietitian reviews current eating habits in order to minimize adverse events and address potential adherence problems. The dietitian alsotailors to each patient's caloric needs to ensure a healthy weight and normal growth is maintained.
  • the dietitian also reviews compliance with the diet and discusses any issues or concerns the patient and his/her parents/legal guardians may have with the diet at Visit 3 (Week ⁇ 3 to Week ⁇ 2).
  • the dietitian informs patients and their parents/legal guardians to call him/her to discuss over the phone or schedule a meeting to address any diet-related questions or concerns any time during the study. Additional resources pertaining to the diet are available to the dietitian and the patient and his/her parent/legal guardian.
  • Weight is measured using a consistent approach at Screening and at each visit after the Run-in Period (i.e., child/adolescent always weighed in same amount of clothing, either in underwear, hospital gowns or by subtracting the weight of clothes). Patients of normal or below normal body weight with weight loss >3% since the last visit are instructed by the dietitian on how to increase caloric intake based on individual needs.
  • the standard recommended fat intake for children >2 years old is to follow a diet with ⁇ 30% energy from fat, hence, decreasing dietary fat intake to ⁇ 20% or ⁇ 30 g fat, whichever is the lesser amount should not pose any risk to patients of any age that may be enrolled in this study.
  • the study consists of 5 periods (see FIG. 2 ):
  • Lomitapide capsules is provided in 4 dose strengths of 2 mg, 5 mg, 10 mg, and 20 mg. Dosing is initiated at the recommended starting dose and escalated to the maximum dose as applicable to the age groups (see Table 1 and FIG. 2 ) based upon safety and tolerability in addition to LDL-C values.
  • Each patient takes 1 to 3 capsule(s) once daily to achieve the doses specified in the titration scheme.
  • the first dose of study medication is administered at the study site on DO.
  • lomitapide As of D1, patients self-administer (or the patient's parent/legal guardian administers to the patient) lomitapide orally, once daily, at approximately the same time each day.
  • lomitapide is administered at least 2 hours after the evening meal (e.g., at bedtime) with a glass of water on an empty stomach because the fat content of a recent meal may adversely impact GI tolerability.
  • Patients who are unable to swallow the intact capsule(s) open the capsule(s) and sprinkle the capsule content on 1 tablespoon of apple sauce or mashed banana, which are fat-free.
  • lomitapide In case of a missed dose, patients are instructed to take missed doses of lomitapide only if they can be taken at least 12 hours prior to the next scheduled dose. Dietary supplements are ideally taken in the morning. Patients taking bile acid sequestrants are reminded that they should take lomitapide 4 hours before or 4 hours after this class of medications. If atorvastatin is given concomitantly, lomitapide is administered 12 hours apart.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US18/018,031 2020-07-29 2021-07-29 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients Abandoned US20230285376A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US18/018,031 US20230285376A1 (en) 2020-07-29 2021-07-29 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US19/341,244 US20260021087A1 (en) 2020-07-29 2025-09-26 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063058211P 2020-07-29 2020-07-29
US18/018,031 US20230285376A1 (en) 2020-07-29 2021-07-29 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
PCT/US2021/043667 WO2022026684A1 (en) 2020-07-29 2021-07-29 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/043667 A-371-Of-International WO2022026684A1 (en) 2020-07-29 2021-07-29 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/489,542 Continuation US12472172B2 (en) 2020-07-29 2023-10-18 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Publications (1)

Publication Number Publication Date
US20230285376A1 true US20230285376A1 (en) 2023-09-14

Family

ID=77398685

Family Applications (3)

Application Number Title Priority Date Filing Date
US18/018,031 Abandoned US20230285376A1 (en) 2020-07-29 2021-07-29 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US18/489,542 Active US12472172B2 (en) 2020-07-29 2023-10-18 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US19/341,244 Pending US20260021087A1 (en) 2020-07-29 2025-09-26 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Applications After (2)

Application Number Title Priority Date Filing Date
US18/489,542 Active US12472172B2 (en) 2020-07-29 2023-10-18 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US19/341,244 Pending US20260021087A1 (en) 2020-07-29 2025-09-26 Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Country Status (10)

Country Link
US (3) US20230285376A1 (https=)
EP (1) EP4188372A1 (https=)
JP (1) JP2023536855A (https=)
KR (1) KR20230047381A (https=)
CN (1) CN116322682A (https=)
AU (1) AU2021316011A1 (https=)
BR (1) BR112023000808A2 (https=)
CA (1) CA3186856A1 (https=)
MX (1) MX2023001202A (https=)
WO (1) WO2022026684A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472172B2 (en) 2020-07-29 2025-11-18 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (https=) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
ATE60571T1 (de) 1984-12-04 1991-02-15 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
KR900001212B1 (ko) 1985-10-25 1990-02-28 산도즈 파마슈티칼스 코오포레이숀 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US4716175A (en) 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
ES2009918A6 (es) 1987-05-22 1989-10-16 Squibb & Sons Inc Procedimiento para preparar inhibidores de hmg-coa-reductasa que contienen fosforo.
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
KR930005040B1 (ko) 1989-08-31 1993-06-12 주식회사 금성사 식기 건조기 겸용 전자레인지 및 그 구동제어방법
US5026554A (en) 1990-09-13 1991-06-25 Merck & Co., Inc. Method of inhibiting fungal growth using squalene synthetase inhibitors
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
DE4435477A1 (de) 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US5536859A (en) 1995-02-27 1996-07-16 Amoco Corporation Alpha-olefin catalyst and process
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
PT832069E (pt) 1995-06-07 2003-06-30 Pfizer Derivados de tetrahidro-isoquinolin-6-il amida do acido bifenilo-2-carboxilico sua preparacao e sua utilizacao como inibidores de proteina de transferencia de triglicerido microsomal e/ou da secrecao de apolipoproteina b (apo b)
DE19546919A1 (de) 1995-12-15 1997-06-19 Bayer Ag N-Heterocyclisch substituierte Phenylessigsäure-Derivate
DE19546918A1 (de) 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
NZ330216A (en) 1996-01-16 2000-09-29 Bristol Myers Squibb Co Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and use in treatment of atherosclerosis
DE19613550A1 (de) 1996-04-04 1997-10-09 Bayer Ag Neue Pyrimido[1,2-a]indole
US6774236B1 (en) 1996-04-04 2004-08-10 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives
DE19613549A1 (de) 1996-04-04 1997-10-09 Bayer Ag Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate
DE19615265A1 (de) 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
TR199802163T2 (xx) 1996-04-30 1999-02-22 Pfizer Inc. 4'-Triflorometilbifenil-2-karboksilik asit
US6057339A (en) 1996-05-09 2000-05-02 Bristol-Myers Squibb Company Method of inhibiting or treating phytosterolemia with an MTP inhibitor
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP0954313A4 (en) 1996-07-24 2003-07-02 Bristol Myers Squibb Co METHOD FOR TREATING TUMORS WITH LOW DENSITY LIPOPROTEIN (LDL) NEEDS USING MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
EA001539B1 (ru) 1996-11-27 2001-04-23 Пфайзер Инк. Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр)
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
AU5513298A (en) 1996-12-20 1998-07-17 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
WO1998031225A1 (en) 1997-01-17 1998-07-23 Bristol-Myers Squibb Company A method of inhibiting or treating phytosterolemia with an mtp inhibitor
WO1998031366A1 (en) 1997-01-17 1998-07-23 Bristol-Myers Squibb Company Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
EP1024804A4 (en) 1997-05-01 2001-03-21 Bristol Myers Squibb Co MTP INHIBITORS AND FAT-SOLUBLE VITAMIN THERAPEUTICS TO REDUCE SERUM LIPIDS
US5990110A (en) 1997-07-15 1999-11-23 Bristol-Meyers Squibb Company Method for treating tumors having high LDL requirements employing MTP inhibitors
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US20020045271A1 (en) 1998-06-10 2002-04-18 Licata And Tyrrell P.C. Compounds and methods for identifying compounds that interact with microsomal triglyceride transfer protein binding sites on apolipoprotein b and modulate lipid biosynthesis
US7358254B2 (en) 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
GEP20033045B (en) 1998-09-17 2003-08-25 Bristol Myers Squibb Co Method for Treating Diabetes
US6509348B1 (en) 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
IL133201A0 (en) 1998-12-04 2001-03-19 Pfizer Prod Inc Lowering blood levels of lipoproten (a)
KR20020002367A (ko) 1998-12-23 2002-01-09 윌리암스 로저 에이 심혈관 징후를 위한 조합물
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
PT1033364E (pt) 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
JP2003505504A (ja) 1999-07-30 2003-02-12 バーケイド，ヘンドリク・ジヤン 糞便による脂肪排泄を増加することによる、非ステロール性内因性疎水性物質の排泄を増加する方法
DE19951022A1 (de) 1999-10-22 2001-04-26 Bayer Ag Carbolinderivate
IL139450A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6812345B2 (en) 2000-06-15 2004-11-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
DE10030375A1 (de) 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
US6649770B1 (en) 2000-11-27 2003-11-18 Ciba Specialty Chemicals Corporation Substituted 5-aryl-2-(2-hydroxyphenyl)-2H-benzotriazole UV absorbers, compositions stabilized therewith and process for preparation thereof
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
JP2002220345A (ja) 2001-01-24 2002-08-09 Sumitomo Pharmaceut Co Ltd 脂肪肝改善剤
IL156585A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
KR100575944B1 (ko) 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
US6884812B2 (en) 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US6916813B2 (en) 2001-12-10 2005-07-12 Bristol-Myers Squibb Co. (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
US20030162788A1 (en) 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
JP3662566B2 (ja) 2002-02-28 2005-06-22 日本たばこ産業株式会社 エステル化合物及びその医薬用途
EP1479666A4 (en) 2002-02-28 2010-10-13 Japan Tobacco Inc ESTER CONNECTION AND THEIR MEDICAL USE
BR0312503A (pt) 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
BR0312825A (pt) 2002-07-23 2005-04-19 Basf Ag Mistura herbicida sinérgica, composição herbicida, processo para a preparação da mesma, e, método de controle de vegetação indesejada
WO2004028544A1 (en) 2002-09-25 2004-04-08 Novo Nordisk A/S Use of mas-compounds for treating diseases associated with lipid metabolism
US20050090426A1 (en) 2003-03-24 2005-04-28 Blumberg Richard S. Methods of inhibiting inflammation
US6846836B2 (en) 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
WO2005000217A2 (en) 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
EP1635773A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. (a New Jersey corp.) Combination therapy for the treatment of hypertension
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
WO2005018436A2 (en) 2003-08-26 2005-03-03 The Trustees Of Boston University Methods for the diagnosis, prognosis and treatment of metabolic syndrome
JP4832897B2 (ja) 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
US7153976B2 (en) 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
MXPA06004005A (es) 2003-10-08 2006-06-28 Vertex Pharma Moduladores de transportadores con casete de union con atp.
ATE428411T1 (de) 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
WO2005051382A1 (ja) 2003-11-28 2005-06-09 Astellas Pharma Inc. 脂質低下作用増強剤
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
JP2007526309A (ja) 2004-03-02 2007-09-13 アベール ファーマシューティカルズ インコーポレイテッド 生物活性剤の混合製剤またはキット
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
WO2005085466A2 (en) 2004-03-09 2005-09-15 Bayer Healtcare Ag Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
GB0405459D0 (en) 2004-03-11 2004-04-21 Shea Clayton O Skipping ropes
WO2005094864A2 (en) 2004-03-30 2005-10-13 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Treatment of hedgehog- and wnt-secreting tumors with inhibitors of lipoprotein particle biogenesis
AU2005230397B2 (en) 2004-04-09 2010-04-08 Elanco Animal Health Ireland Limited Intermittent dosing regimen for the treatment of overweight with MTP-inhibitors
JP4782991B2 (ja) 2004-06-30 2011-09-28 株式会社東芝 情報処理機器および情報処理機器の表示制御方法
JP2008505176A (ja) 2004-06-30 2008-02-21 コンビナトアールエックス インコーポレーティッド 代謝障害を治療するための方法および試薬
KR20070072888A (ko) 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
CA2589654C (en) 2004-12-06 2016-02-16 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
CA2584845C (en) 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
WO2006108666A1 (en) 2005-04-13 2006-10-19 Proteosys Ag Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases
FR2884831B1 (fr) 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
EP1890767A2 (en) 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
MX2008003432A (es) 2005-09-13 2008-03-27 Bayer Cropscience Ag Derivados plaguicidas de bifenilamidina.
AU2006304689A1 (en) 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
US20080051427A1 (en) 2006-05-18 2008-02-28 Fritz Schuckler Pharmaceutical Compositions and Methods of Using Same
US20090042835A1 (en) 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
CA2654183A1 (en) 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
CA2654098A1 (en) 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20080016127A1 (en) 2006-06-30 2008-01-17 Microsoft Corporation Utilizing software for backing up and recovering data
DE102006034907A1 (de) 2006-07-28 2008-01-31 Carl Zeiss Microimaging Gmbh Laser-Scanning-Mikroskop
US20080033019A1 (en) 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
WO2008021353A2 (en) 2006-08-14 2008-02-21 Guangxiang Luo Composition and method for controlling hepatitis c virus infection
US20080103122A1 (en) 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008072061A1 (en) 2006-12-14 2008-06-19 Pfizer Products Inc. Method of treatment of obesity with an mtp inhibitor in conjunction with an increased-fat diet
WO2008075949A1 (en) 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
JP2010513534A (ja) 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
US7645732B2 (en) 2007-01-24 2010-01-12 Board Of Regents, The University Of Texas System Treating hepatitis C virus infection
WO2008090198A1 (en) 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
WO2008115574A1 (en) 2007-03-21 2008-09-25 Reliant Pharmaceuticals, Inc. Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same
FR2922945B1 (fr) 2007-10-31 2009-11-27 Peugeot Citroen Automobiles Sa Procede de determination d'intervalle de maintenance pour vehicule automobile.
WO2010083280A2 (en) 2009-01-14 2010-07-22 Aegerion Pharmaceuticals, Inc. Methods for treating obesity and disorders associated with hyperlipidemia in a mammal
WO2012010212A1 (en) 2010-07-23 2012-01-26 Prysmian S.P.A. Bend-resistant single-mode optical fibre
HK1224186A1 (zh) * 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
BR102015025502B1 (pt) 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
US20170246133A1 (en) * 2016-02-26 2017-08-31 Gemphire Therapeutics Inc. Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
US20180250251A1 (en) * 2016-02-26 2018-09-06 Gemphire Therapeutics Inc. Treatment of Patients with Familial Hypercholesterolemia on Lipid-Lowering Therapy
FI3448426T3 (fi) 2016-04-28 2025-07-18 Regeneron Pharma Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon
CN107773561A (zh) * 2016-08-24 2018-03-09 天津市汉康医药生物技术有限公司 一种甲磺酸洛美他派胶囊及其制备方法
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
CA3208189A1 (en) 2021-03-03 2022-09-09 Mark SUMERAY Methods for treating familial chylomicronemia syndrome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472172B2 (en) 2020-07-29 2025-11-18 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Also Published As

Publication number Publication date
WO2022026684A1 (en) 2022-02-03
US20240058317A1 (en) 2024-02-22
CN116322682A (zh) 2023-06-23
US20260021087A1 (en) 2026-01-22
BR112023000808A2 (pt) 2023-02-07
EP4188372A1 (en) 2023-06-07
JP2023536855A (ja) 2023-08-30
KR20230047381A (ko) 2023-04-07
MX2023001202A (es) 2023-02-23
US12472172B2 (en) 2025-11-18
CA3186856A1 (en) 2022-02-03
AU2021316011A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
US11110074B2 (en) Methods of improving the pharmacokinetics of doxepin
US20260021087A1 (en) Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
JP6456890B2 (ja) ナルトレキソン療法における薬物バイオアベイラビリティの増加
US12201610B2 (en) Compositions comprising aticaprant
KR20210034623A (ko) 다발성 경화증의 치료 및 예방을 위한 방법에서 사용하기 위한 치환된 아미노-피리미딘 화합물
RU2852098C1 (ru) Ломитапид для применения в способах лечения гиперлипидемии и гиперхолестеринемии у педиатрических пациентов
HK40086374A (zh) 在治疗儿科患者的高脂血症和高胆固醇血症的方法中使用的洛美他派
US20220233520A1 (en) Increasing Drug Bioavailability In Naltrexone Therapy
Kingsbury et al. Quetiapine for olanzapine-induced galactorrhea
US20100286200A1 (en) Combination of metformin and an mtp inhibitor
EFFEXOR HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EFFEXOR XR safely and effectively. See full prescribing information for

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

AS Assignment

Owner name: AMRYT PHARMACEUTICALS INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOMPHARMACEUTICALS GMBH;REEL/FRAME:066583/0691

Effective date: 20240131

Owner name: AMRYT PHARMACEUTICALS INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMRYT PHARMACEUTICALS DAC;REEL/FRAME:066583/0630

Effective date: 20230505

Owner name: SOMPHARMACEUTICALS GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUMERAY, MARK;REEL/FRAME:066583/0566

Effective date: 20240130

Owner name: AMRYT PHARMACEUTICALS DAC, IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NALLEN, RUTH;CUNNINGHAM, TRACEY;SIGNING DATES FROM 20230412 TO 20230417;REEL/FRAME:066583/0446

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION RETURNED BACK TO PREEXAM

STCB Information on status: application discontinuation

Free format text: ABANDONED -- INCOMPLETE APPLICATION (PRE-EXAMINATION)